The proportion and spatial distribution of CD8+ T cells at TIME are important determinants of tumor progression, that is, the number and proportion of CD8+ T cells in PTC patients combined with HT is significantly higher than that in PTC patients alone [51]. This evidence concerns the gene CD8A and neoplasm.